Sodium glycerophosphate
Clinical data
Trade namesGlycophos
AHFS/Drugs.comProfessional Drug Facts
Pregnancy
category
  • AU: Exempt
Routes of
administration		Intravenous infusion
ATC code
Legal status
Legal status
  • AU: Unscheduled
Identifiers
  • disodium 3-(phosphonooxy)propane-1,2-diol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC3H7Na2O6P
Molar mass216.036 g·mol−1
3D model (JSmol)
Melting point98 to 100 °C (208 to 212 °F)
Solubility in watervery soluble
  • [Na+].[Na+].OCC(O)COP([O-])([O-])=O
  • InChI=1S/C3H9O6P.2Na/c4-1-3(5)2-9-10(6,7)8;;/h3-5H,1-2H2,(H2,6,7,8);;/q;2*+1/p-2
  • Key:GEKBIENFFVFKRG-UHFFFAOYSA-L
  • Key:OFNNKPAERNWEDD-UHFFFAOYSA-L

Sodium glycerophosphate, sold under the brand name Glycophos, is a medication used to supplement phosphate.[1][2] It is administered via intravenous infusion.[1][2]

Sodium glycerophosphate is an organic phosphate salt.[1][2]

It was approved for medical use in Australia in November 2019.[3][1][4]

It is an unapproved medication in the United States that was used as a substitute for inorganic phosphate during a drug shortage.[2]

Chemistry

The substance is a mixture of disodium glycerol 1- and 2-phosphates, which have different amounts of water of crystallization; the total amount is 5+1⁄2 H2O per glycerol phosphate molecule. It is a white to off-white powder which may or may not be crystalline, has no discernible odor and tastes salty. It melts at 98 to 100 °C (208 to 212 °F) and decomposes at 130 °C (266 °F). Aqueous solutions have a pH of about 9.5.[5]

References

  1. 1 2 3 4 "ARTG Entry:312021 Glycophos Product Information" (PDF). Therapeutic Goods Administration (TGA). Retrieved 23 August 2020.
  2. 1 2 3 4 "Glycophos- sodium glycolate injection, solution". DailyMed. 16 January 2019. Retrieved 23 August 2020.
  3. ↑ "Glycophos Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). Retrieved 23 August 2020.
  4. ↑ "Summary for ARTG Entry:312021 Glycophos sodium glycerophosphate (as hydrate) 4.32 g/20 mL concentrated solution for injection ampoule". Therapeutic Goods Administration (TGA). Archived from the original on 18 April 2021. Retrieved 23 August 2020.
  5. ↑ Hagers Handbuch der pharmazeutischen Praxis (in German). Vol. VI.A (4th ed.). Springer. 15 August 1977. pp. 91–92. ISBN 3-540-05123-6.

Further reading


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.